| Latest Schering Plough News Headlines |
| Date | Time | Source | |
| 09/23/2008 | 4:30PM | PRNUS | Schering-Plough Schedules Conference Call and Webcast for 2008 Third Quarter Earnings
KENILWORTH, N.J., Sept. 23 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) is scheduled to announce its sales and earnings results for the 2008 third quarter on Tuesday, Oct. 21, 2008.
At 8 a.m. (EDT) on that day, Schering-Plough will conduct a conference call to review results for the 2008 third quarter... More...>> |
| 09/23/2008 | 1:00PM | PRNUS | U.S. Pet Owners can Double the Impact of Vaccinations to Help Reduce Rabies in Africa, Save Lives
'Help Here. Change There.' Theme of Vaccination Campaign
MILLSBORO, Del., Sept. 23 /PRNewswire/ -- American pet owners and their animals can help save lives in Africa through vaccinations administered in the U.S. between now and December 31, 2008. Pet owners are invited to double the impact of the annual veterinary... More...>> |
| 09/16/2008 | 11:42AM | PRNUS | Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
KENILWORTH, N.J., Sept. 16 /PRNewswire-FirstCall/ -- The Board of Directors of Schering-Plough Corporation (NYSE:SGP) today declared a quarterly dividend of 6.5 cents per common share. Payment will be made on Nov. 25, 2008, to shareholders of record at the close of business on Nov. 7, 2008. As of June 30, 2008, there... More...>> |
| 09/10/2008 | 5:31PM | PRNUS | Schering-Plough Announces Closing of Planned Divestiture of Selected Animal Health Products to Pfizer
KENILWORTH, N.J., Sept. 10 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) today announced the successful closing of its previously announced transaction with Pfizer Animal Health, to divest certain animal health products from selected franchises in the European Economic Area to Pfizer. These divestments... More...>> |
| 09/10/2008 | 2:57PM | PRNUS | Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
First product launch following acquisition of Organon BioSciences
KENILWORTH, N.J., Sept. 10 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) today announced that the European launch of BRIDION(R) (sugammadex) injection has begun with its introduction this week in Sweden, and that the product is expected... More...>> |
| 08/19/2008 | 7:30AM | PRNUS | Video: ASMANEX(R) TWISTHALER(R) 110 MCG (Mometasone Furoate Inhalation Powder) is Now Available Nationwide for the Maintenance T
ASMANEX is the first and only once-daily inhaled corticosteroid inhaler approved for children as young as age 4
KENILWORTH, N.J., Aug. 19 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) announced today that ASMANEX(R) TWISTHALER(R) 110 mcg (mometasone furoate inhalation powder) is now available in pharmacies... More...>> |
| 08/12/2008 | 8:30AM | PRNUS | Schering-Plough Expands Its Presence in China, Enters Next Stage of Development
KENILWORTH, N.J., Aug. 12 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) today announced that it has expanded its presence in China and established Shanghai Schering-Plough Pharmaceutical Co. Ltd., as a wholly owned operation based in Shanghai through the acquisition of the shares of its former joint... More...>> |
| 08/08/2008 | 7:00AM | PRNUS | Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT fo
ASHBURN, Va., Aug. 8 /PRNewswire/ -- Innocoll, Inc., a privately-held biopharmaceutical company, announced that the last patient has been dosed in the first of three ongoing phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT... More...>> |
| 08/04/2008 | 8:00AM | PRNUS | Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatit
74 percent of patients achieved SVR 12 with 48-week boceprevir-based combination therapy
KENILWORTH, N.J., Aug. 4 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) today reported top-line results from a planned interim analysis of a Phase II study of boceprevir, its investigational oral hepatitis C protease... More...>> |
| 08/01/2008 | 7:00AM | PRNUS | U.S. FDA Issues Action Letter for Sugammadex
KENILWORTH, N.J., Aug. 1 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) today announced that the U.S. Food and Drug Administration (FDA) has issued a "not-approvable" letter for sugammadex sodium injection for the reversal of muscle relaxation during general anesthesia.
"We are surprised and disappointed... More...>> |
| 07/29/2008 | 4:45PM | PRNUS | BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union
BRIDION allows anesthesiologists to rapidly reverse both moderate and deep levels of muscle relaxation
KENILWORTH, N.J., July 29 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) today announced that the European Commission (EC) has approved BRIDION(R) (sugammadex) injection, the first and only selective... More...>> |
| 07/28/2008 | 7:00AM | PRNUS | Innocoll Announces Dosing of First Patient in a Third US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL I
ASHBURN, Va., July 28 /PRNewswire/ -- Innocoll, Inc., a privately-held biopharmaceutical company, announced that the third of a series of planned phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the management of post-operative... More...>> |
| 07/21/2008 | 4:05PM | PRNUS | Schering-Plough Reports Financial Results for Second Quarter of 2008
Broad-Based Performance and Robust Phase III Pipeline Validate Growth and Diversification Strategy; OBS Acquisition Already Contributing to Results
KENILWORTH, N.J., July 21 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) today reported financial results for the second quarter of 2008.
"We are very... More...>> |
| 07/21/2008 | 7:11AM | PRNUS | Innocoll Appoints Anthony H. Wild Ph.D. to Its Board of Directors
ASHBURN, Va., July 21 /PRNewswire/ -- Innocoll Inc. today announced that Anthony H. Wild, Ph.D. has been appointed to its board of directors.
Dr. Wild is a co-founder and General Partner of BOWS Pharmaceuticals AG, a Swiss drug-delivery technology company. He is a member of the Boards of Directors of several privately-owned... More...>> |
| 07/21/2008 | 6:45AM | PRNUS | Schering-Plough Reschedules Time of Conference Call, Webcast for 2008 Second Quarter Earnings to Later Today
KENILWORTH, N.J., July 21 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) has rescheduled the time of its conference call and webcast to review the sales and earnings results for the 2008 second quarter to approximately 4:45 p.m. (EDT) from 8 a.m. today. The quarterly financial results will be issued... More...>> |
| 07/17/2008 | 10:40AM | PRNUS | NASONEX(R) Now Approved in Japan for the Treatment of Allergic Rhinitis in Adult Patients
KENILWORTH, N.J., July 17 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) today announced that Schering-Plough K.K., the company's country operation in Japan, has received marketing approval for NASONEX(R) (mometasone furoate monohydrate) Nasal Spray 50mcg* for the treatment of allergic rhinitis in... More...>> |
| 07/15/2008 | 10:41AM | PRNUS | Summits Research Releases Comments on HD, WFC, SGP, CL, and SAF
CHICAGO, July 15 /PRNewswire-FirstCall/ -- Seven Summits Research releases NewsBites on key stocks.
Seven Summits Strategic Investments NewsBites are available to all investors at:
http://www.go7now.com/nb/0715Y (Note: You may have to copy this link into your browser then press the [ENTER] key.)
Today's Seven Summits... More...>> |
| 07/11/2008 | 10:19AM | PRNUS | Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Fr
EORTC 18991 Phase III Study Results Published in The Lancet
KENILWORTH, N.J., July 11 /PRNewswire-FirstCall/ -- Today, Schering-Plough (NYSE:SGP) and the EORTC announced that long-term treatment with pegylated interferon alfa-2b in stage III melanoma patients had a significant and sustained impact on relapse-free survival... More...>> |
| 07/08/2008 | 9:50AM | PRNUS | Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
Corifollitropin alfa meets primary endpoints in ENGAGE Trial
KENILWORTH, N.J., July 8 /PRNewswire-FirstCall/ -- Schering-Plough Corp., (NYSE:SGP) announced today that corifollitropin alfa, its experimental, sustained follicle stimulant (SFS) met its primary endpoints in the Phase III ENGAGE trial, according to data... More...>> |
| 07/03/2008 | 10:40AM | PRNUS | Seven Summits Research Releases Comments on INTC, X, AET, VIP, and SGP
CHICAGO, July 3 /PRNewswire/ -- Seven Summits Research releases NewsBites on key stocks.
Seven Summits Strategic Investments NewsBites are available to all investors at:
http://www.go7now.com/nb/0703Y (Note: You may have to copy this link into your browser then press the [ENTER] key.)
Today's Seven Summits Strategic... More...>> |